To be clear: Ozempic is a diabetes drug while Wegovy is the weight loss counterpart. This “new" molecule does NOT address glucose management by improving sensitivity to insulin nor improving insulin response to the consumption of carbs. This new molecule will also NOT have a protective nor regenerative effect on pancreatic beta cell islets as GLP-1 does.
This, strictly, appears to target satiety for weight loss.
The only relation to semaglutide is that it's a peptide and it promotes weight loss. It has no other similarites with GLP-1. The comparison only exists to indicate efficacy of intended effect.
#Diabetes #Ozempic #GLP1
https://twit.social/@twitnews/114138689351869590